-
Scribe Therapeutics Announces Pricing of Upsized Initial Public Offering
July 23, 2026 21:08 ET | Source: Scribe Therapeutics Inc. ALAMEDA, Calif., July 23, 2026 (GLOBE NEWSWIRE) — Scribe Therapeutics Inc. (“Scribe Therapeutics”) (Nasdaq: SCTX), a clinical-stage biotechnology company engineering purpose-built in vivo CRISPR technologies designed to extend healthy lifespan through disease prevention and durable therapeutic intervention, today announced the pricing of its upsized initial…
Latest News
About the Author
We increase the awareness of millions of users through our news networks. We are one of the most trusted news networks in the world.
